Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 2365 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Transgenomic Declares Q4 2008 Results

Gross profit from continuing operations was $3.4 million or 55% during the fourth quarter of 2008 compared to $3.9 million or 60% during the comparable period of 2007.

Impax files ANDA for generic Doryx tablets 150mg

Once the abbreviated new drug application (ANDA) is approved by FDA, Global Pharmaceuticals, Impax’s generic division, will commercialize the products. Doryx is a tetracycline-class antibacterial indicated for rickettsial

EXACT Sciences Appoints New CEO, CFO

Jeffrey R. Luber and Charles R. Carelli Jr., present president and chief executive, and chief financial officer of the company, respectively, have agreed to resign their present positions